RX-3117 (Synonyms: TV-1360; Fluorocyclopentenylcytosine)

Name: RX-3117
Brand: MedChemExpress
SKU: HY-15228
Rating: 5.0 (1 reviews)

Cat. No.: HY-15228 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

RX-3117 (TV-1360) is a potent and orally active anticancer and antimetaboliteagent. RX-3117 inhibits DNA methyltransferase 1 (DNMT1). RX-3117 shows antiproliferative and anti-tumour activity. RX-3117 induces cell cycle arrest at S phase and apoptosis.

For research use only. We do not sell to patients.

RX-3117 Chemical Structure

CAS No. : 865838-26-2

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 566	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 566	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 200	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 420	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 580	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE RX-3117

•bioRxiv. 2023.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.5 μM Compound: 5a	Antitumor activity against human A549 cells by SRB method Antitumor activity against human A549 cells by SRB method	[PMID: 22524616]
HCT-116	IC₅₀	0.19 μM Compound: 5a	Antitumor activity against human HCT116 cells by SRB method Antitumor activity against human HCT116 cells by SRB method	[PMID: 22524616]
HeLa	IC₅₀	1.35 μM Compound: 5a	Antitumor activity against human HeLa cells by SRB method Antitumor activity against human HeLa cells by SRB method	[PMID: 22524616]
HepG2	IC₅₀	0.79 μM Compound: 5a	Antitumor activity against human HepG2 cells by SRB method Antitumor activity against human HepG2 cells by SRB method	[PMID: 22524616]
HT-29	IC₅₀	0.28 μM Compound: 5a	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 22524616]
K562	IC₅₀	0.82 μM Compound: 5a	Antitumor activity against human K562 cells by SRB method Antitumor activity against human K562 cells by SRB method	[PMID: 22524616]
LNCaP	IC₅₀	2.67 μM Compound: 5a	Antitumor activity against human LNCAP cells by SRB method Antitumor activity against human LNCAP cells by SRB method	[PMID: 22524616]
MCF7	IC₅₀	0.34 μM Compound: 5a	Antitumor activity against human MCF7 cells by SRB method Antitumor activity against human MCF7 cells by SRB method	[PMID: 22524616]
MDA-MB-231	IC₅₀	0.18 μM Compound: 5a	Antitumor activity against human MDA-MB-231 cells by SRB method Antitumor activity against human MDA-MB-231 cells by SRB method	[PMID: 22524616]
MKN-45	IC₅₀	0.34 μM Compound: 5a	Antitumor activity against human MKN45 cells by SRB method Antitumor activity against human MKN45 cells by SRB method	[PMID: 22524616]
NCI-H226	IC₅₀	0.25 μM Compound: 5a	Antitumor activity against human NCI-H226 cells by SRB method Antitumor activity against human NCI-H226 cells by SRB method	[PMID: 22524616]
OVCAR-3	IC₅₀	0.8 μM Compound: 5a	Antitumor activity against human OVCAR3 cells by SRB method Antitumor activity against human OVCAR3 cells by SRB method	[PMID: 22524616]
PANC-1	IC₅₀	0.62 μM Compound: 5a	Antitumor activity against human PANC1 cells by SRB method Antitumor activity against human PANC1 cells by SRB method	[PMID: 22524616]
PC-3	IC₅₀	0.63 μM Compound: 5a	Antitumor activity against human PC3 cells by SRB method Antitumor activity against human PC3 cells by SRB method	[PMID: 22524616]
SK-MEL-28	IC₅₀	1.38 μM Compound: 5a	Antitumor activity against human SK-MEL-28 cells by SRB method Antitumor activity against human SK-MEL-28 cells by SRB method	[PMID: 22524616]
U-251	IC₅₀	0.83 μM Compound: 5a	Antitumor activity against human U251 cells by SRB method Antitumor activity against human U251 cells by SRB method	[PMID: 22524616]

In Vitro

RX-3117 causes both inhibition of DNA and RNA synthesis^[1].
RX-3117 (11.7, 21 μM; 48 h) shows antiproliferative activity in A549, SW1573 cells^[1].
RX-3117 is activated by uridine-cytidine kinase 2 (UCK2)^[1].
RX-3117 (1-25 μM; 72 h) inhibits the growth of HCT-116, MDA-MB-231, PANC-1, Caki-1, MCF7, A549, MKN45, U251 cells with IC₅₀s of 0.39, 0.18, 0.62, 0.84, 0.34, 0.34, 0.50, 0.83 μM, respectively^[2].
RX-3117 (5, 10 μM; 4 days) induces cell cycle arrest at S phase and apoptosis^[2].
RX-3117 (1-5 μM; 24 h) decreases the cellular amount of DNMT1 in a dose-dependent manner in MDA-MB-231^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	A549, SW1573 cells
Concentration:	11.7, 21 µM
Incubation Time:	48 h
Result:	Showed antiproliferative activity in A549 (63.7% cell growth), SW1573 cells (59% cell growth).

Apoptosis Analysis^[2]

Cell Line:	A549, SW1573 NSCLC cells
Concentration:	5 µM for A549 cells, 10 µM for SW1573 cells
Incubation Time:	4 days
Result:	Induced cell cycle arrest at S phase and apoptosis.

In Vivo

RX-3117 (2, 10 mg/kg; i.p.; three times per week for five weeks) shows anti-tumour activity in nude mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (human colon carcinoma HCT116 xenograft model)^[3]
Dosage:	2, 10 mg/kg
Administration:	I.p.; three times per week for five weeks
Result:	Caused significant inhibition of tumor growth at the doses of 2 and 10 mg/kg.

Clinical Trial

Molecular Weight

257.22

Formula

C₁₀H₁₂FN₃O₄

CAS No.

865838-26-2

Appearance

Solid

Color

White to off-white

SMILES

O=C1N([C@@H]2C(F)=C(CO)[C@@H](O)[C@H]2O)C=CC(N)=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (194.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.8877 mL	19.4386 mL	38.8772 mL
5 mM	0.7775 mL	3.8877 mL	7.7754 mL
10 mM	0.3888 mL	1.9439 mL	3.8877 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (276 KB) SDS (252 KB)

COA (251 KB) HNMR (248 KB)

Handling Instructions (2659 KB)

References

[1]. Sarkisjan D, et al. The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2. PLoS One. 2016 Sep 9;11(9):e0162901. [Content Brief]

[2]. Balboni B, et al. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. [Content Brief]

[3]. Fahy J, et al. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012 Dec;22(12):1427-42. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.8877 mL	19.4386 mL	38.8772 mL	97.1931 mL
	5 mM	0.7775 mL	3.8877 mL	7.7754 mL	19.4386 mL
	10 mM	0.3888 mL	1.9439 mL	3.8877 mL	9.7193 mL
	15 mM	0.2592 mL	1.2959 mL	2.5918 mL	6.4795 mL
	20 mM	0.1944 mL	0.9719 mL	1.9439 mL	4.8597 mL
	25 mM	0.1555 mL	0.7775 mL	1.5551 mL	3.8877 mL
	30 mM	0.1296 mL	0.6480 mL	1.2959 mL	3.2398 mL
	40 mM	0.0972 mL	0.4860 mL	0.9719 mL	2.4298 mL
	50 mM	0.0778 mL	0.3888 mL	0.7775 mL	1.9439 mL
	60 mM	0.0648 mL	0.3240 mL	0.6480 mL	1.6199 mL
	80 mM	0.0486 mL	0.2430 mL	0.4860 mL	1.2149 mL
	100 mM	0.0389 mL	0.1944 mL	0.3888 mL	0.9719 mL

RX-3117 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RX-3117865838-26-2TV-1360 FluorocyclopentenylcytosineRX3117RX 3117TV1360TV 1360Nucleoside Antimetabolite/AnalogApoptosisorally activeantiproliferativeanti-tumourDNMT1apoptosisS phaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

RX-3117 (Synonyms: TV-1360; Fluorocyclopentenylcytosine)

Customer Review

RX-3117 Related Antibodies

1 Publications Citing Use of MCE RX-3117

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

RX-3117 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

RX-3117 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report